Influenza is a disease of public health importance due to the substantial seasonal morbidity and mortality and the high pandemic potential of its aetiologic agents, influenza viruses. Diagnosis of influenza is mainly based on laboratory testing (i.e. molecular testing) of nasopharyngeal samples....

This document presents ECDC's generic protocol for a prospective multi-country cohort study to evaluate the effectiveness of the COVID-19 vaccine in hospital-based health workers, which was used to implement the study from March 2022. This document outlines standardised methods for establishing...

The overall aim of the study is to monitor near real-time performance of COVID-19 vaccines administered as part of 2023 autumnal vaccination campaigns in the community-dwelling resident population aged ≥65 years in EU/EEA countries to detect any variation in VE, so that public health vaccine...

This core protocol for ECDC studies of VE against hospitalisation with severe acute respiratory infection (SARI) laboratory-confirmed with SARS-CoV-2 or with influenza, version 4.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine...

The end of 2019 saw the emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19). As of October 2023, almost 276 million cases and more than 2.2 million deaths had been reported in the WHO European Region [1]. As of October...

This protocol describes the common methodology to be applied to established health data registries across seven participating European Union/European Economic Area (EU/EEA) Member States to estimate vaccine effectiveness for Coronavirus disease 2019 (COVID-19) in children and adolescents aged...

This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living...

This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries. This work is performed within the Vaccine Effectiveness, Burden and...

This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses, against hospitalisation due to COVID-19 and COVID-19 related deaths in resident populations ≥50 years of age, living in the community, in six European countries: Belgium,...

This document presents the core protocol for ECDC studies of CVE and IVE against symptomatic laboratoryconfirmed influenza or SARS-CoV-2 infection, respectively, at primary care level. This core protocol presents the main elements for a multicentre (multi-country) study of IVE/CVE at primary...